Medidelta Inc. began the research and development of cervical cancer screening software in 2001. This research has resulted in an automated cervical smear screening software, designed for detection of pre-cancerous lesions. Medidelta is currently launching its first product Cytopath. This product provides healthcare professionals with accurate and cost-effective diagnostic results.

Presently Medidelta is embarking on a mission to create sales and brand recognition, targeting hospitals, clinical laboratories and health organizations directed at improving women's health. The company is continuing its research and development efforts, and hopes to expand upon its current product.